A Randomised Placebo-controlled Study to Evaluate the Effects of GSK2256294 Following Repeat Dosing on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions
Latest Information Update: 26 Jun 2023
At a glance
- Drugs GSK 2256294 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society
- 03 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 12 Apr 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov